NIH study finds two doses of HPV vaccine may be as protective as full course
, by DCEG Staff
Two doses of the human papillomavirus (HPV) vaccine Cervarix were as effective as the current standard three-dose regimen after four years of follow-up, according to researchers from the National Cancer Institute (NCI), part of the National Institutes of Health, and their colleagues. The results of the study, based on data from a community-based clinical trial of Cervarix in Costa Rica, appeared online Sept 9, 2011, in the Journal of the National Cancer Institute.
NCI Cancer Bulletin (Archive): HPV vaccine study in Costa Rica yields insights on cancer prevention
News article in the NCI newsletter the Cancer Bulletin (Archive)